Communiqués Dr. Reddy's Laboratories Limited

Actions

DRREDDY

INE089A01031

Produits pharmaceutiques

Temps Différé Bombay S.E. Autres places de cotation 07:13:36 20/07/2026			Varia. 5j.	Varia. 1 janv.
1 215,20 ^INR	+0,36%		-1,57%	-4,39%

13/07	Les actions asiatiques cotées aux États-Unis sous forme d'ADR progressent lors de la séance de lundi	MT
10/07	Les actions asiatiques cotées aux États-Unis sous forme d'ADR progressent lors de la séance de vendredi	MT

Communiqués

29/06	Dr. Reddy's Laboratories Limited Announces Filing of Annual Report on Form 20-F	AQ
26/06	Dr. Reddy’s Laboratories Limited Announces Filing of Annual Report on Form 20-F	BU
22/06	Dr Reddy Laboratories : Life Cycle Assessment Report Consolidated (8 Products) (PwCxDRL Consolidated LCA Report 8 Products Web upload)	PU
13/06	Dr. Reddy’s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States	BU
29/05	Dr Reddy Laboratories : Annual Report for Fiscal Year Ending March 31, 2026 (Form 20-F)	PU
16/05	Dr. Reddy's Laboratories Launches its Generic Semaglutide Injection in Canada	BU
12/05	Doctor Reddy's: Fiscal Q4 Earnings Snapshot	AQ
12/05	Dr Reddy Laboratories : . Reddy’s Q4 & Full Year FY26 Financial Results	PU
29/04	Dr. Reddy's Laboratories Announces Health Canada Approval for Generic Semaglutide Injection in Canada	BU
29/04	Dr Reddy Laboratories : Announces Health Canada Approval for Generic Semaglutide Injection in Canada	PU
23/02	Dr. Reddy's Announces USFDA Acceptance to Review Its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, Abatacept	AQ
20/02	Dr. Reddy’s Announces USFDA Acceptance to Review Its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, Abatacept	BU
19/02	Dr Reddy Laboratories : . Reddy’s forays into Hormone Replacement Therapy segment with acquisition of Progynova® and Cyclo- Progynova® in India	PU
06/02	Dr Reddy Laboratories : Landscape Analysis on Alternatives to Animal Testing for Drug Development in India	PU
29/01	Dr Reddy Laboratories : Corporate Governance Report	PU
21/01	Dr Reddy Laboratories : IFRS Consolidated Q3 FY 2025-26	PU
21/01	Dr Reddy Laboratories : INDAS Standalone Q3 FY 2025-26	PU
21/01	Dr Reddy Laboratories : INDAS Consolidated Q3 FY 2025-26	PU
21/01	Doctor Reddy's: Fiscal Q3 Earnings Snapshot	AQ
21/01	Dr Reddy Laboratories : . Reddy’s Q3 & 9MFY26 Financial Results	PU
15/01	Dr. Reddy's announces the first-to-market launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7%, the generic equivalent of Extra-Strength Pataday Once Daily Relief, in the U.S.	AQ
14/01	Dr. Reddy’s Announces the First-to-Market Launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), the Generic Equivalent of Extra-Strength Pataday® Once Daily Relief, in the U.S.	BU
14/01	Dr Reddy Laboratories : . Reddy’s announces the first-to-market launch of Olopatadine Hyochloride Ophthalmic Solution USP, 0.7% (OTC), the generic equivalent of Extra-Strength Pataday® Once Daily Relief, in the U.S.	PU
06/01	Dr Reddy Laboratories : . Reddy's launches Hevaxin®, a novel recombinant Hepatitis E vaccine in India	PU
03/12	Aurigene Oncology Limited annonce des données initiales encourageantes provenant des deux premiers groupes de l'étude de phase 1 évaluant l'AUR112, un inhibiteur oral à petites molécules de MALT1, pour les lymphopathies malignes...	BU